We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current CLDX market cap is 2.37B. The company's latest EPS is USD -2.1458 and P/E is -19.56.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 967k | 267k | 1.52M | 4.13M | 156k |
| Operating Income | -32.47M | -33.21M | -41.24M | -47.63M | -40.61M |
| Net Income | -29.36M | -30.5M | -38.26M | -43.31M | -32.81M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 4.87M | 11.64M | 6.06M | 9.22M | 6.88M |
| Operating Income | -53.23M | -63.35M | -71.24M | -115.23M | -154.54M |
| Net Income | -50.88M | -59.78M | -70.51M | -112.33M | -141.43M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 324.52M | 299.31M | 280.26M | 465.63M | 868.85M |
| Total Liabilities | 21.78M | 21.77M | 33.54M | 36.46M | 30.23M |
| Total Equity | 302.74M | 277.54M | 246.72M | 429.17M | 838.61M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 122.93M | 235.84M | 444.65M | 352.74M | 465.63M |
| Total Liabilities | 28.91M | 26.48M | 25.18M | 26.53M | 36.46M |
| Total Equity | 94.03M | 209.36M | 419.48M | 326.2M | 429.17M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -28.57M | -55.77M | -74.76M | -107.29M | -40.64M |
| Investing | 52.57M | 53.73M | 65.38M | -105.78M | -315.21M |
| Financing | 694k | 827k | 1.08M | 218.46M | 436.11M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -46.42M | -40.4M | -60.91M | -103.73M | -107.29M |
| Investing | 17.08M | -98.22M | -216.16M | 89.94M | -105.78M |
| Financing | 16.26M | 171.23M | 272.37M | 4.08M | 218.46M |
| Market Cap | 2.37B |
| Price to Earnings Ratio | -19.56 |
| Price to Sales Ratio | 402.11 |
| Price to Cash Ratio | 79.48 |
| Price to Book Ratio | 6.45 |
| Dividend Yield | - |
| Shares Outstanding | 65.91M |
| Average Volume (1 week) | 812.97k |
| Average Volume (1 Month) | 610.21k |
| 52 Week Change | 4.11% |
| 52 Week High | 53.18 |
| 52 Week Low | 22.11 |
| Spread (Intraday) | 60.25 (62.6%) |
| Company Name | Celldex Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.celldex.com |
| Industry | in vitro,in vivo diagnostics (2835) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
